Shares of the European-based GLP-1 weight-loss drugmaker fell further on the heels of strong numbers put out Eli Lilly Proves Its GLP-1 Dominance Again, Raising My Price Target Summary Eli Lilly delivered robust Q4 results, with revenue up 43% YoY and EPS beating consensus by $0.61
The drugs delayed gastric emptying can suppress thirst cues, and side effects like nausea or diarrhea can increase fluid loss
Why Consider B-12 Injections
Tirzepatide Efficacy: The SURMOUNT-1 trial showed that participants on the highest 15 mg dose achieved a mean weight reduction of 22.5% after 72 weeks
PlexusDx offers transparent, flat-rate pricing with no dose-based increases
GLP-1 therapy has also shown benefit in improving atherothrombosis markers (e.g., inflammation, endothelial dysfunction, clotting in this population